SEKISUI CHEMICAL: Victory in German Patent Infringement Lawsuit Concerning PVB Interlayer Films
Article content
TOKYO — The High Performance Plastics Company (President : Akira Asano) of SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Keita Kato; hereinafter 'SEKISUI CHEMICAL') hereby notifies that it has obtained judgments in its favor (hereinafter referred to as 'the Judgments') from the District Court Munich I on April 17, 2025, in the patent infringement litigation (docket No. 7 O 12401/24 and 7 O 12476/24) against Kuraray Europe GmbH (hereinafter referred to as 'Kuraray Europe'), a subsidiary of Kuraray Co., Ltd which we previously announced in the press release dated October 16, 2024, titled 'Filing of Lawsuit Seeking Injunction and Damages for Patent Infringement in Relation to PVB Interlayer in Germany.'
Article content
Article content
This judgments found that the sound-insulating wedge products manufactured and sold by Kuraray Europe, namely ''Trosifol' The Wedge Acoustic' and ''Trosifol' The Wedge Acoustic Shadeband' (hereinafter collectively referred to as 'Kuraray Products') infringe European Patent No. 2017237 and European Patent No. 3208247 owned by SEKISUI CHEMICAL, which relate to the sound insulation property of a PVB interlayer. Additionally, the Judgments permit SEKISUI CHEMICAL to enforce measures such as a recall in addition to an injunction against the Kuraray Products, provided that SEKISUI CHEMICAL pays a security deposit.
Kuraray Europe may appeal the Judgments.
Article content
SEKISUI CHEMICAL Group regards its intellectual property rights as an important management resource. It will continue to take strict action in cases where it determines that our intellectual property rights have been infringed.
Article content
Headquartered in Japan, SEKISUI CHEMICAL CO., LTD. (TOKYO: 4204) and its subsidiaries make up the SEKISUI CHEMICAL Group. 26,000 employees in over 156 companies throughout 20 countries and regions aim to contribute to improving the lives of the people of the world and the earth's environment. Thanks to a history of innovation, dedication and a pioneering spirit, SEKISUI CHEMICAL now holds leading positions in its three diverse business divisions as well as top global market share in interlayer film, foam products, conductive particles and more.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Bachem Mourns the Loss of Company Founder Dr. H.C. Peter Grogg
Bubendorf, Switzerland--(Newsfile Corp. - June 3, 2025) - The founder and honorary chairman of Bachem (SIX: BANB) Peter Grogg, passed away on Monday, June 2, 2025, at the age of 83. Peter Grogg founded Bachem in 1971 and built the company from a two-person operation into the global market leader for the chemical synthesis of peptides. Peter Grogg was CEO of the company for over 30 years until 2002 and Chairman of the Board of Directors of Bachem Holding AG until 2012. His daughter Nicole Grogg Hötzer has served as Vice-Chairwoman of the Board since 2011. For his achievements and merits in the field of peptides, Peter Grogg was awarded an honorary doctorate by the University of Basel. Kuno Sommer, Chairman of the Board of Directors of Bachem: "With Peter Grogg, we have lost a great entrepreneur. His drive and values made Bachem an internationally successful company and have left a lasting mark on it. In doing so, he has written a chapter of Swiss economic history. On behalf of the Board of Directors, the Executive Committee, and all employees of Bachem, I would like to express our deepest condolences to his wife, his two children, and their families." About Bachem Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments. To view the source version of this press release, please visit
CTV News
3 hours ago
- CTV News
B.C. Premier David Eby makes first stop on Asia trade mission in Tokyo
B.C. Premier David Eby touched down in Japan's Tokyo as part of a 10-day trade mission across Asia. B.C. Premier David Eby has touched down in Tokyo, Japan, as part of a 10-day trade mission across Asia. Running from June 1 to June 10, the trip will also see Eby visit the Japanese city of Osaka, as well as Kuala Lumpur in Malaysia and Seoul in South Korea, in a trip designed to diversify and strengthen B.C.'s economy amid the ongoing tariff war with the U.S. On Monday, Eby released a video to social media site X of himself navigating Japanese supermarket Seijo Ishii and perusing the goods that were for sale – a number of which were B.C.'s very own. 'I found Hard Bite chips right out of Surrey, B.C., and then Real Earth chocolates out of Pitt Meadows,' he said, holding up the packages of homegrown snacks to the camera. 'We've got the best food in the world, and it's right here, at just a regular store in Japan.' In the video, Eby said he was embarking on his visit to 'make sure more B.C. products end up on the shelf.' The store visit came after being welcomed and briefed by Canada's ambassador to Japan, Ian McKay, Monday morning. Our province has some of the best quality products in the world. Picked up some of BC's very own @Hardbite Chips and Real Earth Bounty chocolates at Seijo Ishii in Tokyo. Our work to diversify trade overseas supports good paying jobs in BC. — David Eby (@Dave_Eby) June 2, 2025 Eby, who will be accompanied by representatives from B.C. businesses and research universities alongside Lana Popham, minister of agriculture and food, and Paul Choi, parliamentary secretary for Asia-Pacific trade, plans to discuss a range of B.C. products during his excursion, including softwood lumber and liquified natural gas. 'Our largest trading partner has become increasingly unreliable, so now is the time to expand international markets for B.C. goods and develop deeper bonds with other countries,' Premier Eby said in a statement released a few weeks prior to his trip. 'This trade mission is about showcasing all that B.C. has to offer, deepening our relationship with major customers, supporting good jobs here at home and building our province's position as the economic engine of a stronger and more independent Canada.' Eby flew out Saturday, one day after U.S. President Donald Trump announced he will be doubling the tariffs on steel and aluminum imports to 50 per cent.
